BrainStorm Cell Therapeutics to Transition Listing to OTCQB Market
New York, NY – July 17, 2025 – BrainStorm Cell Therapeutics, a leading clinical-stage biotechnology company focused on developing innovative cell therapies for debilitating neurodegenerative diseases, announced today its voluntary decision to delist its common stock from The Nasdaq Capital Market. The company expects its last day of trading on Nasdaq to be on or around August 15, 2025. Concurrently, BrainStorm Cell Therapeutics plans to transition its listing to the OTCQB Venture Market, a trading platform operated by OTC Markets Group.
This strategic move is intended to provide greater operational flexibility and potentially reduce certain costs associated with maintaining a Nasdaq listing. The company anticipates that the transition to OTCQB will allow it to focus more resources on its core mission: advancing its promising pipeline of cell therapies, including its lead candidate NurOwn®, for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
“This decision was made after careful consideration and is a strategic step to align our trading venue with our current operational and financial objectives,” said [Insert Name and Title of a Company Representative, if available in the original source, otherwise omit or use a generic title like “a spokesperson for BrainStorm”]. “We believe that trading on the OTCQB will offer us the agility needed as we continue to progress our clinical programs and work towards bringing potentially life-changing therapies to patients.”
BrainStorm Cell Therapeutics remains committed to transparency and will continue to provide timely updates on its progress to its stakeholders. The company is working with Nasdaq to ensure a smooth transition process and expects its common stock to commence trading on the OTCQB Market shortly after its Nasdaq delisting. Shareholders are advised to consult with their financial advisors regarding the implications of this transition.
The company’s pipeline, particularly NurOwn®, has shown encouraging results in clinical trials, offering hope to patients and families affected by ALS. BrainStorm Cell Therapeutics continues to be dedicated to scientific rigor and patient advocacy as it navigates this transition and pursues its therapeutic development goals. Further details regarding the delisting and OTCQB listing will be made available on the company’s investor relations website in due course.
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB’ at 2025-07-17 20:30. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.